Horizon Pharma USA Inc

Deals

CCYSZE(M)TNRMTYRNKMOSPFITYPEBNCHIPTGDNCSPRDCPNNICPRICE
USD600.0008Feb-29Sr. UnsecuredB1B+-FixedTsy-5.50% a3535.50%-100.00000
Tranche Comments
8 yr: Redemption: 2022-08-01; Registration: 144A/Reg S; Comments: USD1.5bn (upsized from US$1bn) 10NC5 144A/Reg S. CS/JPM/Barc/BNPP/Citi/CA-CIB/DB/GS/MS/RBC/Scotia/TD. Px talk 6.50%-6.75%. Priced at par, 6.5%MWC+50bp. Call sched: 2/1/24 at 103.250%, 2/1/25 at 102.167%, 2/1/26 at 101.083%, 2/1/27 at 100. Eq claw: 40% at 106.500% CoC: 101%. (Source: IFR);
Use of Proceeds
Refinancing

B&I

BWICS & Inventory

This module is available on the Professional plan. Learn moreUpgrade Plan

TRACE

This module is available on the Professional plan. Learn moreUpgrade Plan

Research